Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
4 hedge funds and large institutions have $74K invested in Dermata Therapeutics Warrant in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
33% less funds holding
Funds holding: 6 → 4 (-2)
36% less capital invested
Capital invested by funds: $115K → $74K (-$41K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1K |
DRMAW Hedge Fund Activity: Q2 2022 in Review
4 of the 5,878 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q2 2022, worth a combined $74K — down 36% from $115K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DRMAW and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Virtu Financial, exiting entirely with an estimated $3K sold.
- 4 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q2 2022, down from 6 in Q1 2022.
- Funds reported $74K of Dermata Therapeutics Warrant stock for Q2 2022, down 36% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q2 2022 and 2 closed out, a net change of -2 holders.
- The largest Dermata Therapeutics Warrant seller in Q2 2022 was Virtu Financial, an estimated $3K sold.
Based on aggregated 13F filings for Q2 2022.